Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias

Abstract

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

1 - 62 . (canceled) 
     
     
         63 . A pharmaceutical composition comprising a first population of immune cells comprising an exogenous nucleic acid molecule encoding a protein and a mutated endogenous CDS gene and a second population of immune cells comprising a mutated endogenous CD5 gene, wherein the second population does not comprise the exogenous nucleic acid molecule encoding the protein. 
     
     
         64 . The pharmaceutical composition of  claim 63 , wherein the immune cell is a lymphocyte. 
     
     
         65 . The pharmaceutical composition of  claim 63 , wherein the immune cell is a T-cell. 
     
     
         66 . The pharmaceutical composition of  claim 63 , wherein the mutated endogenous CD5 gene is a gene edited endogenous CDS gene. 
     
     
         67 . The pharmaceutical composition of  claim 64 , wherein the mutated endogenous CDS gene is a gene edited endogenous CD5 gene. 
     
     
         68 . The pharmaceutical composition of  claim 65 , wherein the mutated endogenous CD5 gene is a gene edited endogenous CDS gene. 
     
     
         69 . The pharmaceutical composition of  claim 63 , wherein the mutated CD5 gene is a CRISPR mutated CD5 gene. 
     
     
         70 . The pharmaceutical composition of  claim 64 , wherein the mutated CD5 gene is a CRISPR mutated CD5 gene. 
     
     
         71 . The pharmaceutical composition of  claim 65 , wherein the mutated CD5 gene is a CRISPR mutated CD5 gene. 
     
     
         72 . The pharmaceutical composition of  claim 63 , wherein the first and second population of immune cells comprising the mutated endogenous CD5 gene has a decrease in expression of endogenous CD5 protein. 
     
     
         73 . The pharmaceutical composition of  claim 64 , wherein the first and second population of immune cells comprising the mutated endogenous CD5 gene has a decrease in expression of endogenous CD5 protein. 
     
     
         74 . The pharmaceutical composition of  claim 65 , wherein the first and second population of immune cells comprising the mutated endogenous CD5 gene has a decrease in expression of endogenous CD5 protein. 
     
     
         75 . The pharmaceutical composition of  claim 63 , wherein the protein encoded by the exogenous nucleic molecule does not comprise an antigen binding domain that binds to CD5. 
     
     
         76 . The pharmaceutical composition of  claim 64 , wherein the protein encoded by the exogenous nucleic molecule does not comprise an antigen binding domain that binds to CD5. 
     
     
         77 . The pharmaceutical composition of  claim 65 , wherein the protein encoded by the exogenous nucleic molecule does not comprise an antigen binding domain that binds to CD5.